Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Has results × Carcinoma × pertuzumab × Clear all

Sponsor

Conditions

Breast Neoplasms 41 Ovarian Neoplasms 4 Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Solid Tumor 2 Rectal Neoplasms 2 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Inflammatory Breast Neoplasms 2 HER2-positive Breast Cancer 2 Colonic Neoplasms 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Patient Preference 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Neoplasms, Unknown Primary 1 Multiple Endocrine Neoplasia 1 Malignant Solid Neoplasm 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 Her2-Positive Breast Cancer 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Early Breast Cancer 1 Fallopian Tube Neoplasms 1 Carcinoma, Neuroendocrine 1 Carcinoid Tumor 1 Breast Neoplasms, Male 1 Biliary Tract Neoplasms 1

Interventions

Carboplatin 21 Cisplatin 14 pembrolizumab 12 Paclitaxel 12 Gemcitabine 12 Pemetrexed 9 130-nm albumin-bound paclitaxel 9 Everolimus 8 Cetuximab 6 durvalumab 5 Fluorouracil 5 Docetaxel 5 Cyclophosphamide 5 Axitinib 5 Albumin-Bound Paclitaxel 5 osimertinib 4 Sunitinib 4 Radiotherapy 4 Nivolumab 4 Ipilimumab 4 Erlotinib Hydrochloride 4 Sorafenib 3 Radiotherapy, Intensity-Modulated 3 Radiation 3 Octreotide 3 Irinotecan 3 Bevacizumab 3 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3 vosaroxin 2 pralsetinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡